sinc
emerg
brazil
may
mosquitoborn
zika
viru
zikv
rais
global
concern
due
associ
signific
rise
number
infant
born
microcephali
neurolog
disord
syndrom
develop
prototyp
subunit
adenoviralbas
zika
vaccin
encod
extracellular
portion
zikv
envelop
gene
e
fuse
fibritin
foldon
trimer
domain
efl
subunit
vaccin
deliv
intraderm
carboxymethyl
cellulos
microneedl
array
mna
immunogen
two
vaccin
name
zikvrefl
test
mice
primeboost
immun
regimen
associ
induct
zikvspecif
antibodi
respons
provid
neutral
immun
moreov
protect
evalu
sevendayold
pup
virul
zikv
intraperiton
challeng
pup
born
mice
immun
protect
lethal
challeng
infect
without
weight
loss
neurolog
sign
pup
born
dam
immun
mnazikvrefl
partial
protect
protect
seen
pup
born
phosphat
buffer
salineimmun
mice
studi
illustr
preliminari
efficaci
e
zikv
antigen
vaccin
control
zikv
infect
provid
promis
candid
vaccin
antigen
format
prevent
zika
viru
diseas
zika
viru
zikv
mosquitoborn
flaviviru
flavivirida
famili
first
identifi
uganda
viru
recent
attract
global
attent
due
rapid
spread
brazil
countri
america
dick
et
al
zanluca
et
al
zikv
outbreak
brazil
associ
signific
rise
number
babi
born
microcephali
zanluca
et
al
neurolog
disord
syndrom
declar
global
emerg
world
health
organ
http
wwwwhointmediacentrefactsheetszikaen
http
cdc
http
wwwcdcgov
zika
concern
spread
zikv
northern
hemispher
concomit
morbid
spur
search
effect
vaccin
zikv
relat
dengu
yellow
fever
japanes
enceph
west
nile
virus
wnv
arthropodborn
flavivirus
like
flavivirus
zikv
contain
posit
singlestrand
genom
rna
encod
polyprotein
proteolyt
process
yield
three
structur
protein
capsid
c
precursor
membran
prm
envelop
e
seven
nonstructur
protein
dick
et
al
succes
develop
flaviviru
vaccin
began
year
ago
yellow
fever
liveattenu
vaccin
monath
sinc
n
million
peopl
vaccin
protect
year
persist
vaccineinduc
immun
barrett
teuwen
howev
sever
sever
advers
event
associ
vaccin
administr
observ
last
year
thu
purifi
inactiv
vaccin
recent
develop
test
result
suggest
good
immunogen
toler
monath
et
al
week
ago
two
studi
show
immunogen
plasmid
dna
adenoviru
serotyp
express
viruslik
particl
mice
nonhuman
primat
publish
abbink
et
al
build
initi
find
develop
effect
zikv
vaccin
describ
develop
recombin
adenovir
vector
express
codonoptim
zikv
e
antigen
subunit
recombin
zikv
e
vaccin
deliv
transcutan
carboxymethyl
cellulos
cmc
microneedl
array
mna
bediz
et
al
korkmaz
et
al
investig
abil
induc
neutral
immun
respons
assess
abil
passiv
protect
zikv
challeng
novel
neonat
zikv
infect
mous
model
construct
padzikvefl
gene
encod
human
secretori
signal
peptid
hidden
markov
model
sphmm
mwwrlww
llllllllwpmvwa
extracellular
portion
zikv
strain
envelop
gene
genbank
defin
amino
acid
polyprotein
bamh
ilink
fibritin
foldon
trimer
domain
gsgyipeaprdgqayvrkdgewvllstfl
tobacco
etch
viru
proteas
tp
enlyfeg
six
histidin
tag
codonoptim
optim
express
mammalian
cell
use
upgen
codon
optim
algorithm
gao
et
al
padzikvefl
gener
subclon
codonoptim
zikvefl
gene
shuttl
vector
pad
genbank
salinoti
site
subsequ
replicationdefect
adenoviru
design
gener
loxp
homolog
recombin
moreov
also
purifi
recombin
protein
name
zikvrefl
supernat
use
ni
superflow
resin
clontech
nativ
condit
use
subunit
vaccin
briefli
supernat
human
embryon
kidney
hek
cell
infect
heatinactiv
min
mix
volum
bind
buffer
mm
imidazol
mm
nacl
mm
sodium
phosphat
ph
ni
superflow
resin
clontech
previous
equilibr
equilibr
buffer
mm
imidazol
mm
nacl
mm
sodium
phosphat
ph
ad
mixtur
incub
overnight
rotat
next
day
settl
resin
mix
pack
empti
column
column
wash
ml
equilibr
buffer
three
time
follow
ml
wash
buffer
mm
imidazol
mm
nacl
mm
sodium
phosphat
ph
three
time
elut
ml
elut
buffer
mm
imidazol
mm
nacl
mm
sodium
phosphat
ph
eluat
concentr
desalt
phosphat
buffer
salin
pb
amicon
filter
millipor
desalt
step
repeat
three
time
concentr
purifi
recombin
zikvefl
determin
bradford
assay
use
bovin
serum
albumin
bsa
protein
standard
zikv
stock
provid
dr
rober
tesh
univers
texa
medic
branch
vero
cell
infect
zikv
moi
incub
monolay
show
signific
cytopath
effect
cultur
supernant
clarifi
centrifug
min
viru
precipit
overnight
addit
nacl
polyethylen
glycol
centrifug
min
viral
pellet
redissolv
origin
volum
pb
centrifug
sucros
gradient
h
follow
dialysi
pb
buffer
viru
dilut
proper
concentr
trehalos
buffer
mm
tri
ph
mm
nacl
mm
mgcl
trehalos
tween
kept
viru
titer
vero
cell
seed
sixwel
plate
cell
per
well
next
day
cell
infect
log
dilut
zikv
h
overlay
methyl
cellulos
media
contain
fetal
bovin
serum
three
day
infect
cell
stain
crystal
violet
plaqu
count
titer
calcul
multipli
number
plaqu
dilut
divid
infect
volum
sixto
eightweekold
femal
mice
five
anim
per
group
inocul
subcutan
sc
viral
particl
vp
pb
neg
control
intraderm
id
mna
coat
zikvrefl
two
week
primari
immun
mice
boost
intranas
id
dose
respect
immunogen
mice
bled
retroorbit
sinu
week
serum
sampl
evalu
zikv
antibodi
enzymelink
immunosorb
assay
elisa
plaqu
reduct
neutral
assay
prnt
immun
studi
protocol
approv
univers
pittsburgh
institut
anim
care
use
committe
follow
evalu
passiv
protect
matern
antibodi
pup
obtain
mate
nonimmun
male
immun
femal
three
week
follow
booster
vaccin
pup
challeng
intraperiton
ip
zikv
seven
day
birth
two
nonchalleng
pup
litter
use
control
bled
day
birth
determin
passiv
matern
antibodi
physic
condit
pup
observ
bodi
weight
measur
daili
day
exhibit
loss
bodi
weight
defin
onset
diseas
addit
mice
found
dead
mice
weight
loss
exceed
highest
bodi
weight
euthan
record
dead
sever
neurolog
sign
score
describ
previous
yoshii
et
al
sign
paralysi
loss
balanc
associ
viral
infect
score
absent
present
sever
score
paralysi
assign
follow
normal
drag
limb
invers
dorsum
pedi
complet
paralysi
spontan
movement
score
loss
balanc
assign
follow
normal
lean
head
trunk
postur
one
side
inabl
retain
postur
fall
one
side
circl
movement
one
side
total
score
quantifi
express
mean
standard
error
mean
sera
anim
collect
everi
two
week
test
zikvspecif
igg
convent
elisa
briefli
elisa
plate
coat
pfu
heatinactiv
zikv
min
per
well
overnight
carbon
coat
buffer
mm
ph
block
pb
contain
tween
pbst
bsa
h
mous
sera
dilut
pup
sera
pbst
bsa
incub
h
plate
wash
hrpconjug
antimous
igg
santacruz
ad
well
incub
h
plate
wash
three
time
develop
reaction
stop
h
absorb
nm
determin
use
elisa
reader
biotek
instrument
determin
plaqu
reduct
neutral
titer
week
pool
sera
mous
sera
dilut
twofold
serial
dilut
incub
pfu
zikv
serumfre
media
h
subsequ
ad
vero
cell
monolay
densiti
cell
grown
sixwel
tissu
cultur
plate
incub
h
incub
inocul
remov
semisolid
media
ad
plate
incub
addit
five
day
titer
express
reciproc
highest
serum
dilut
still
give
reduct
plaqu
number
prnt
rel
sampl
incub
preimmun
control
pool
sera
vitro
experi
paper
repeat
least
twice
data
shown
mean
replic
standard
error
statist
analysi
student
ttest
oneway
analysi
varianc
tukey
multipl
comparison
test
logrank
mantelcox
test
perform
use
graph
pad
prism
version
softwar
san
diego
california
usa
result
consid
statist
signific
p
valu
b
symbol
use
indic
p
valu
respect
gener
recombin
adenoviru
serotyp
vector
encod
human
secretori
signal
peptid
hidden
markov
model
sphmm
follow
codonoptim
extracellular
portion
zikv
e
gene
fuse
fibritin
foldon
trimer
domain
zikvefl
moreov
zikvefl
antigen
engin
polyhistidinetag
tobacco
etch
viru
tev
proteas
cleavag
sequenc
facilit
downstream
purif
fig
replicationdefect
adenoviru
design
gener
loxp
homolog
recombin
previous
describ
kim
et
al
hardi
et
al
recombin
zikvrefl
protein
purifi
supernat
hek
cell
line
use
ni
superflow
resin
nativ
condit
packag
subunit
vaccin
mna
mnazikvefl
test
abil
mnazikvrefl
elicit
specif
antizikv
immun
respons
vivo
mice
inocul
sc
vp
id
mnazikvrefl
pb
day
follow
booster
immun
day
dose
id
respect
fig
week
post
prime
immun
sera
obtain
mice
screen
presenc
zikvspecif
antibodi
use
elisa
analysi
zikvspecif
antibodi
detect
soon
two
week
first
immun
sera
mice
vaccin
p
mice
immun
mnazikvrefl
show
signific
titer
four
week
booster
immun
p
b
compar
sera
mice
immun
pb
fig
furthermor
qualit
neutral
activ
zikv
antibodi
test
prnt
assay
presenc
zikvneutr
antibodi
shown
mnazikvrefl
although
respons
mice
immun
mnazikvrefl
fourto
lower
respons
achiev
mice
immun
expect
neutral
antibodi
respons
observ
control
anim
group
fig
find
support
premis
mnazikvreflbas
zikv
e
antigen
vaccin
abl
induc
neutral
zikvspecif
immun
understand
vaccin
induc
zikv
especif
immun
neutral
zikv
vivo
protect
anim
pathogen
effect
develop
passiv
protect
suckl
mous
model
build
upon
knowledg
dick
et
al
day
day
old
suckl
mice
suscept
zikv
infect
via
ip
rout
show
neurolog
sign
pup
obtain
mate
immun
femal
nonimmun
male
mice
week
booster
immun
pup
challeng
ip
seven
day
birth
pfu
zikv
monitor
daili
mortal
weigh
day
mean
time
diseas
onset
weight
loss
slightli
earlier
pup
pbsimmun
mice
mnazikvreflimmun
mice
although
differ
signific
vs
day
p
tabl
pup
born
pbsimmun
mice
show
bodi
weight
loss
day
postinfect
howev
weight
loss
mnazikvrefl
pup
reduc
signific
differ
found
day
p
b
p
b
day
challeng
compar
pb
pup
weight
loss
observ
pup
born
dam
immun
vaccin
signific
differ
measur
pup
mice
unchalleng
control
pup
entir
period
signific
differ
start
day
p
b
p
b
day
challeng
compar
pb
pup
fig
surviv
rate
pup
two
anim
group
also
monitor
challeng
zikv
surviv
rate
observ
pup
mnazikvreflimmun
dam
respect
wherea
surviv
rate
seen
pup
pbsimmun
dam
fig
differ
pup
pbsimmun
dam
pup
mnazikvimmun
dam
statist
signific
p
p
respect
pup
mnazikvrefland
pbsimmun
dam
compar
signific
differ
surviv
rate
observ
p
indic
vaccin
candid
effici
passiv
protect
neonat
mice
lethal
zikv
challeng
expect
pup
pbsimmun
dam
show
neurolog
sign
includ
loss
balanc
paresi
hindlimb
paralysi
neurolog
score
howev
five
six
pup
mnazikvreflimmun
dam
exhibit
neurolog
ill
signific
differ
percentag
pb
group
p
although
neurolog
sever
score
significantli
lower
pup
pbsimmun
mice
p
b
contrast
pup
mice
show
mild
symptom
one
time
point
sign
neurolog
ill
tabl
lastli
detemin
relationship
surviv
rate
maternallytransf
antibodi
sera
nonchalleng
pup
born
immun
dam
collect
test
reactiv
zikv
elisa
level
matern
igg
zikvspecif
antibodi
measur
pup
nurs
dam
significantli
higher
pup
nurs
pbsimmun
dam
p
b
howev
pup
nurs
mnazikveflimmun
dam
level
igg
antibodi
zikvrefl
significantli
higher
compar
pup
nurs
pbsimmun
dam
fig
data
suggest
surviv
rate
pup
correl
maternallytransf
antibodi
igg
titer
although
anim
immun
mnazikvefl
protect
level
zikvspecif
igg
transfer
newborn
suboptim
studi
describ
construct
immunolog
evalu
two
zikv
vaccin
candid
initi
evalu
indic
zikv
vaccin
mnazikvrefl
elicit
humor
immun
respons
immun
mice
humor
c
b
ns
fig
character
zikvspecif
immun
respons
induc
mnazikvrefl
experiment
schedul
repres
immun
timelin
mice
n
immun
subcutan
viral
particl
adzikvefl
pb
neg
control
boost
intranas
amount
adenoviru
two
week
later
mnazikvrefl
administ
intraderm
deliveri
b
zikvspecif
igg
antibodi
level
measur
indic
time
point
use
elisa
c
zikvneutr
titer
week
postimmun
measur
use
vero
cell
determin
reciproc
highest
serum
dilut
still
give
reduct
plaqu
number
prnt
rel
sampl
incub
preimmun
control
pool
sera
static
signific
differ
tukey
test
mark
bar
asterisk
p
b
p
b
mean
neutral
detect
two
independ
neutral
test
combin
mous
sera
respons
character
high
titer
antibodi
e
antigen
confirm
elisa
well
neutral
titer
confirm
prnt
assay
importantli
pup
born
immun
dam
zikvspecif
immun
passiv
transfer
protect
day
challeng
pfu
zikv
strain
mnazikvrefl
vaccin
engin
use
brazil
zikv
strain
strain
e
protein
differ
strain
e
protein
use
challeng
three
amino
acid
ident
gener
zikv
envelop
protein
highli
conserv
although
present
studi
adenovirusbas
vaccin
potent
two
test
zikv
vaccin
candid
acknowledg
least
like
among
two
candid
translat
clinic
product
preval
antiadenoviru
serotyp
antibodi
human
limit
use
suitabl
clinic
vaccin
platform
howev
experiment
use
serotyp
adenoviralbas
vaccin
shown
studi
invalu
tool
antigen
vaccin
select
given
pathogen
convers
mnadeliv
zikv
vaccin
mnazikvrefl
although
optim
induc
neutral
immun
current
format
clinic
applic
vaccin
platform
target
infecti
diseas
zikv
geometr
design
mnabas
vaccin
platform
afford
uniqu
advantag
effici
deliveri
target
superfici
skin
microenviron
rich
antigenpres
cell
immunogen
lower
observ
previous
report
adjuv
inactiv
whole
viru
vaccin
mnabas
vaccin
offer
safeti
clinic
advantag
defin
recombin
subunit
antigen
potenti
local
codeliveri
adjuv
low
dose
codeliveri
tlr
ligand
adjuv
low
concentr
substanti
increas
immunogen
influenza
subunit
vaccin
weldon
et
al
importantli
fabric
process
mna
afford
uniqu
product
advantag
reproduc
safeti
manufactur
distribut
critic
widespread
clinic
deploy
thu
current
futur
effort
toward
clinic
translat
zikv
vaccin
direct
toward
test
comparison
differ
e
antigen
format
dimer
vs
trimer
clinic
relev
antigenadjuv
format
codeliv
mna
one
thing
learn
present
zikv
vaccin
studi
yield
product
zikv
envelop
e
subunit
protein
low
current
format
find
also
confirm
recent
publish
zikv
vaccin
studi
similar
previous
observ
flavivirus
taylor
et
al
low
yield
e
protein
probabl
due
absenc
prem
import
protein
stabil
instanc
express
wnv
e
protein
alon
show
proteolyt
cleavag
compar
e
protein
produc
presenc
prem
taylor
et
al
thu
inclus
prem
sequenc
seem
import
prerequisit
zikv
ebas
vaccin
develop
importantli
studi
use
immunocompet
mous
challeng
model
zikv
infect
approach
inspir
public
dick
et
al
zikv
shown
pathogen
newborn
mice
although
model
recapitul
zikv
pathogenesi
observ
human
effect
model
evalu
vivo
neutral
activ
vaccineinduc
zikv
immun
conduct
experi
mani
mous
model
zikv
infect
establish
interferon
receptordefici
mice
sjl
mice
cugola
et
al
shah
kumar
miner
et
al
dowal
et
al
lazear
et
al
rossi
et
al
investig
sjl
mice
closest
clinic
model
fetal
microcephali
consid
evalu
effici
vaccin
candid
futur
supplementari
data
articl
found
onlin
http
dx
fig
protect
zikv
infect
neonat
mice
matern
immun
mnzzikvrefl
pup
obtain
mate
nonimmun
male
immun
femal
five
week
prime
vaccin
pup
challeng
intraperiton
seven
day
birth
zikv
bodi
weight
surviv
b
monitor
day
postinfect
statist
signific
differ
tukey
test
logrank
mantelcox
test
mark
bar
asterisk
p
b
p
b
p
b
